AN2 Therapeutics Pauses Trial: Efficacy Concerns Rise
AN2 Therapeutics voluntarily pauses enrollment in its epetraborole clinical trial due to lower efficacy. Safety is not a concern. The ...
- Latest
- Trending
AN2 Therapeutics voluntarily pauses enrollment in its epetraborole clinical trial due to lower efficacy. Safety is not a concern. The ...
Analysts predict AI-integrated iPhones could boost Apple's stock and sales, potentially leading to more device replacements and revenue opportunities.
Renowned analyst Eric Krown predicts Ethereum's rally will continue towards the low $3000s, highlighting its strength, bullish technical indicators, and ...
Actively managed strategies and AI investments are fueling growth in the ETF industry. The industry is expanding its offerings and ...
Saudi Arabia's state-oil giant, Aramco, is considering a share sale in 2024, pending shareholder approval. This could lead to further ...
Oppenheimer lowers price target on Gilead Sciences after Q4 earnings report and challenges in drug pipeline. Optimistic about prospects for ...
Take-Two Interactive's price target is adjusted to $180 by Wolfe Research, citing strong performance and potential for earnings growth.
Investment company Investcorp plans to list a portfolio company in the Gulf region by 2024, with optimism for completion in ...
Babcock & Wilcox secures $13 million contract to provide environmental equipment to a North American petroleum refinery. The deal includes ...
Joby Aviation stock rises 4.2% as company secures exclusive deal for air taxi services in Dubai, positioning them as a ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.